

Updates in IOL Technology

Zaina Al-Mohtaseb, MD
Whitsett Vision Group
Cataract, Refractive, & Cornea Surgeon
Director of Research
Clinical Associate Professor, Baylor College of Medicine
SEC 2024

Financial Disclosure

- I have the following financial interests or relationships to disclose:
 - Alcon
 - Zeiss
 - Bausch + Lomb
 - Johnson & Johnson
 - Allergan
 - Visus
 - Vista
 - Ocular Therapeutix
 - Tarsus
 - Dompe
 - Kala
 - BVI
 - Trefoil
 - CorneaGen
 - OcuPhire

Introduction

- Increasing expectations
- Cataract surgery now a refractive procedure
- Accuracy, repeatability, and consistency



Expectations

I choose ONE of the following vision correction options for this eye: RIGHT LEFT

1. Basic cataract surgery with a single-vision lens for best:

Distance vision (e.g., driving, watching TV)

Intermediate vision (e.g., computer, dashboard)

Near vision (e.g., reading a book)

I realize that I may need to wear glasses or contact lenses even after surgery to get best vision at my preferred choice (listed above) and will certainly require glasses (or contact lenses) to see at the other two distances.

2. *Astigmatism correction with either incisions in the cornea or a special lens implant ("toric" lens) and additional procedures (as indicated) to aim for best vision without glasses for:

Distance vision (e.g., driving, watching TV)


Intermediate vision (e.g., computer, dashboard)

Near vision (e.g., reading a book)

My goal is to have good vision without glasses at my preferred choice (listed above). I understand that I may still require glasses or contact lenses to get my absolute best vision at my preferred distance. In addition, I understand that I will still require glasses or contact lenses to see at other distances.

Avoid Refractive Errors

- Accurate keratometry & biometry
- Optimize IOL calculations
- Rule out ocular pathology
 - Cornea
 - Retina
- Set appropriate expectations & educate



Clinical Ophthalmology

Dovepress

open access to scientific and medical research

Open Access Full Text Article

ORIGINAL RESEARCH

Causes and correction of dissatisfaction after implantation of presbyopia-correcting intraocular lenses

This article was published in the following Dove Press journal:
Clinical Ophthalmology
11 October 2016
Number of times this article has been viewed

Allister Gibbons
Tayyeba K Ali
Daniel P Waren
Kendall E Donaldson

Department of Ophthalmology,
Bascom Palmer Eye Institute,
University of Miami Miller School
of Medicine, Miami, FL, USA

Purpose: The purpose of this study was to assess the causes and possible solutions for patient dissatisfaction after the implantation of presbyopia-correcting intraocular lenses (IOLs).

Methods: This study was a retrospective review of clinical records. All patients who were seen between January 2009 and December 2013 whose primary reason for consultation was dissatisfaction with visual performance after presbyopia-correcting IOL implantation were included in the study. A single treating physician, who determined the most probable cause of dissatisfaction, decided which interventions to pursue following the initial consultation.

Results: Data from 74 eyes of 49 patients were analyzed. The most common cause for complaint was blurry or foggy vision both for distance and near (68%). Complaints were most frequently attributed to residual refractive error (57%) and dry eye (35%). The most common interventions pursued were treatment of refractive error with glasses or contact lenses (46%) and treatment for dry eye (24%). Corneal laser vision correction was done in 8% of eyes; 7% required an IOL exchange. After the interventions, 45% of patients had completed resolution of symptoms, 23% of patients were partially satisfied with the results, and 32% remained completely dissatisfied with the final results.

Conclusion: The most identifiable causes of dissatisfaction after presbyopia-correcting IOL implantation are residual refractive error and dry eye. Most patients can be managed with conservative treatment, though a significant number of patients remained unsatisfied despite multiple measures.

Keywords: intraocular lens, cataract, presbyopia, multifocal intraocular lens

Testing

- Refraction
- Topography
- Biometry
- OCT macula

Measurements of cornea before manipulation or drops applied

Testing: Refraction

- Make sure vision commiserate with cataract
- Outcomes of first eye
- Evaluate axis of astigmatism
- Ensure IOL power makes sense
- Posterior corneal astigmatism






Testing: Topography




Importance of Topography

- To rule out corneal pathology
 - Ocular surface disease
 - Salzmann's
 - EBMD
 - Fuchs



Why Does it Matter?



- 77% had corneal staining;
63% had decreased TBUT
- Many of these patients were asymptomatic
- Can impact topography and biometry
- Can negatively affect surgical outcomes
 - Decrease goblet cell density, TBUT, & corneal sensitivity



Trattler WB, et al. Clinical Study Report: Cataract and Dry Eye: prospective health assessment of cataract patients ocular surface study. 2010.

Screen for Retinal Abnormalities

- ERM
- Macular degeneration
- Drusen
- Results in decreased contrast sensitivity—
compounded with multifocals
- Can initially evaluate with IOL Master 700
- Importance of OCT macula for premium expectations




Lens Technology

- Multifocal IOLs
 - Alcon Clareon Panoptix
 - J&J Odyssey
- Light Adjustable Lens for Post-Refractive
- Aphthera Pinhole Optic for Irregular Corneas

Alcon

Clareon. PanOptix. Trifocal IOL

20/20 NEAR, INTERMEDIATE, AND DISTANCE VISION IS NOW POSSIBLE WITH CLAREON® PANOPTIX®^{1†}



See PanOptix® IOL visual acuity through 13 in


¹Based on mean value of binocular defocus curve at near, intermediate and distance (0 m to infinity).
[†]Snellen Acuity measured through IOL. A Snellen of 20/20 is better indicating IOL is better, which means for most the 5 Day Treatment Diabetic Retinopathy Study patients in the lens was not needed.

Alcon

Clareon. PanOptix. Trifocal IOL

PANOPTIX® PROVIDES AN UNINTERRUPTED RANGE OF VISION³

PanOptix® provides an uninterrupted range of vision of 20/25 or better from -3.0D to distance.^{3†*}



At -3.0D (13 in) PanOptix® shows visual acuity of 20/25 or 0.1 logMAR³


^{*}Distance and binocular visual acuity (0.0 to -4.0 D) was pooled from 5 PanOptix® studies in cataract patients (N=62) at 36mo.
[†]1.5D to -4.0D (13 in) to -2.5D (10 in) at 36 months.

PATIENT-REPORTED VISUAL DISTURBANCES¹

Results from a patient-prompted and validated QUID questionnaire at 6 months when asked: "In the past 7 days, how much were you bothered with starbursts, halos, and glare?"

Most bothersome visual disturbances. Percent of patients bothered very much by:

- 4.8% by starbursts (n=125)
- 2.4% by halos (n=127)
- 1.6% by glare (n=126)




¹ QUID® (QUD) is a validated patient-reported questionnaire for measuring patient-reported visual symptoms. QUID is a registered trademark of Alcon.

ACCURACY IN ASTIGMATISM CORRECTION

The high rotational stability of the Clareon® Toric IOL instills the confidence that comes from predictable performance.^{1†}

95.3% of Clareon® Toric IOLs rotate ≤5° between surgery and day 1 measures^{1† †}

A mean absolute rotation of 1.8° at day 1 post-op and 2° at 6 months post-op (n=124)^{1† †}



[†] In an additional analysis, 98.4% of Clareon® IOLs (n=127) had an absolute rotation of ≤5° between surgery and 6 months.
^{††} Mean rotation at day 1 (n=127) and 6 months (n=124): 1.8° ±3.7° ±3.9°, respectively. Study measures were taken at baseline (immediately after surgery, <1 hour), at day 1, and at months 1, 3, and 6.

Take Home Points- PanOptix

- Newer generation diffractive optic multifocal IOL (quadfocal)
- Likely the most versatile range of focus of diffractive optic IOL's
- Not all patients are candidates, requires a clean visual axis
- Quality of distance vision may be decreased compared with monofocal
- Newer Clareon material may improve quality of distance vision


Patient Case

- **65 y/o male**
- **CC:** Decreased distance vision in the recent year with more difficulty seeing street signs and watching TV, which has been gradually progressing over the past 3-4 years. He sees ghosting of images and is bothered by glare from lights.
- **MRx: OD:** -3.75 + 1.25 x 176 **OS:** -4.50 + 0.75 x 130
- **Ocular/Medical/Surgical History:**
 - Myopia OU
- **Patient's desired visual outcomes:**
 - Prefers no glasses after surgery; has never worn glasses for reading.
 - Want to be able to drive comfortably at night and will tolerate slight imperfections (halos, or rings around lights)


Exam Data

	OD	OS
WEARING:	-3.75 + 1.25 x 176 ccVA: 20/70	-4.50 + 0.75 x 130 ccVA: 20/30
MRX:	-3.75 + 1.25 x 170 ccVA: 20/40+2	-2.50 + 0.75 x 005 ccVA: 20/30 NI
PUPILS:	PERRLA, Bright: 3.5 mm, Dim: 4.0 mm	PERRLA, Bright: 3.5 mm, Dim: 4.0 mm
IOP:	13	13
SLE: L/C/S: Cornea: A/C: Iris: Lens:	conjunctivochalasis, meibomian gland dysfunction clear and compact cornea normal depth and quiet iris flat 2+ milky NS	conjunctivochalasis, meibomian gland dysfunction clear and compact cornea normal depth and quiet iris flat 2+ milky NS
DFE: Optic Nerve: Vitreous: Retina:	no disc edema or pallor, C/D 0.3 posterior vitreous detachment normal macula and retina, no holes or tears	no disc edema or pallor, C/D 0.3 posterior vitreous detachment normal macula and retina, no holes or tears

iTrace



iTrace




IOL Master 700

OD right				Biometric values				OS left				
L.S. Phakic				vs. Vitreous body				L.S. Phakic				
Ref. ---				VA. ---				Ref. ---				
LVC: Untreated								LVC: Untreated				
AL: 23.61 mm				SD: 4 μm				AL: 23.57 mm				
CCT: 575 μm				SD: 3 μm				CCT: 584 μm				
ACD: 2.62 mm				SD: 8 μm				ACD: 2.78 mm				
LT: 5.11 mm				SD: 11 μm				LT: 5.19 mm				
AL	CCT	ACD	LT	AL	CCT	ACD	LT	AL	CCT	ACD	LT	
23.61 mm	575 μm	2.81 mm	5.11 mm	23.56 mm	584 μm	2.79 mm	5.19 mm	23.61 mm	574 μm	2.81 mm	5.12 mm	
23.61 mm	574 μm	2.81 mm	5.12 mm	23.58 mm	584 μm	2.79 mm	5.19 mm	23.61 mm	576 μm	2.81 mm	5.12 mm	
23.61 mm	579 μm	2.82 mm	5.11 mm	23.57 mm	583 μm	2.78 mm	5.19 mm	23.61 mm	579 μm	2.82 mm	5.18 mm	
Corneal values												
SE: 43.95 D	SD: 0.02 D	SE: 43.91 D	SD: 0.02 D	SE: 43.95 D	SD: 0.03 D	SE: 43.92 D	SD: 0.02 D	SE: 43.93 D	SD: 0.02 D	SE: 43.93 D	SD: 0.02 D	
K1: 43.55 D @ 72°	SD: 0.05 D	K1: 43.54 D @ 116°	SD: 0.03 D	K2: 44.35 D @ 162°	SD: 0.02 D	K2: 44.29 D @ 26°	SD: 0.02 D	ΔK: +0.80 D @ 162°	SD: 0.02 D	ΔK: +0.75 D @ 26°	SD: 0.02 D	
SE: 43.93 D	ΔK: +0.87 D @ 160°	SE: 43.90 D	ΔK: +0.77 D @ 24°	SE: 43.95 D	ΔK: +0.81 D @ 162°	SE: 43.92 D	ΔK: +0.72 D @ 27°	SE: 43.96 D	ΔK: +0.72 D @ 165°	SE: 43.93 D	ΔK: +0.76 D @ 27°	
TSE: 43.80 D	SD: 0.03 D	TSE: 43.87 D	SD: 0.00 D	TK1: 43.33 D @ 79°	SD: 0.09 D	TK1: 43.46 D @ 108°	SD: 0.05 D	TK2: 44.27 D @ 169°	SD: 0.03 D	TK2: 44.29 D @ 18°	SD: 0.04 D	
ΔTK: +0.94 D @ 169°	SD: 0.03 D	ΔTK: +0.83 D @ 18°	SD: 0.04 D	TSE: 43.77 D	ΔTK: +0.98 D @ 166°	TSE: 43.87 D	ΔTK: +0.90 D @ 19°	TSE: 43.79 D	ΔTK: +1.05 D @ 169°	TSE: 43.87 D	ΔTK: +0.73 D @ 18°	
TSE: 43.84 D	ΔTK: +0.82 D @ 173°	TSE: 43.87 D	ΔTK: +0.88 D @ 17°	White-to-white and pupil values								
WTW: 12.0 mm	lx: +0.5 mm	ly: +0.1 mm	WTW: 11.9 mm	lx: -0.6 mm	ly: +0.2 mm							
P: 5.2 mm	CW-chord: 0.5 mm @ 172°							P: 3.9 mm	CW-chord: 0.3 mm @ 337°			
Image stored				Reference image				Image stored				


Pentacam

OCULUS - PENTACAM 4 Maps Selectable




Pentacam

OCULUS - PENTACAM 4 Maps Selectable





OCT Macula



Diagnosis/ Treatment Plan

- Treatment: **OD** DRN00V +21.0 D
One 40 degree LRI @ 349 meridian
- OS** DRN00V +21.0 D
One 35 degree LRI @ 210



Case Outcome


1 MTH PO	OD			OS		
UCVA:	DVA: 20/20	IVA: 20/25 @ 32"	NVA: J1 @ 14"	DVA: 20/25-2	IVA: 20/20 @ 32"	NVA: J1 @ 14"
UCVA OU:	DVA: 20/20-2		IVA: 20/20 @ 32"	NVA: J1+ @ 14"		
MRX:	Plano sph	VA: 20/20		-0.25 +0.50 x 012	VA: 20/20+1	
IOP:	13			11		
IOL USED:	DRN00V +21.D, LRI @ 349			DRN00V +21.D, LRI @ 210		
SLE:	WNL			WNL		
DFE:	WNL			WNL		

Patient states vision is doing well and he can see without needing glasses for any distance. Halos and glare has decreased with little glare issues since surgery. Colors are very vibrant now!

Technologies and what they can deliver

TECNIS Odyssey™ all-new smooth diffractive design

TECNIS Synergy™



TECNIS Odyssey™




Distance visual acuity

Binocular UCDDVA¹

- Mean visual acuity 20/20
- 81.2% 20/20 or better
- 92.8% 20/25 or better

Binocular BCDVA¹

- Mean visual acuity 20/20
- 92.5% 20/20 or better



Retrospective analysis of reported outcomes: Binocular UCDDVA n=69; Binocular BCDVA n=53


Near visual acuity

Binocular UCVA¹

- Mean visual acuity J1
- 77.1% J1 or better
- 92.9% J2 or better
- 97.1% J3 or better


Binocular DCNVA¹

- Mean visual acuity J1
- 86.0% J1 or better
- 97.7% J2 or better
- 100% J3 or better



Spectacle independence

Spectacle Wear at 1 Month




Over 96% of TECNIS Odyssey™ IOL patients did not require spectacles at any distance.¹

Johnson & Johnson

L Data on File (2023) DOF2023CT4061

*Q: "Was the patient prescribed glasses at the conclusion of the 1-month visit?"
Three subjects 3/83 (1 subject for distance, 1 subject for near, and 1 subject for both distance and near)

Dysphotopsias



Retrospective analysis of reported outcomes, n=96. Three subjects reported severe halo (n=3/96) in both eyes. Two subjects reported severe night glare (n=2/96) in both eyes. For subjects who reported a symptom but did not specify a severity in the chart (8.3%), data were classified as mild in the graph above.

3.1% Severe halo



2.1% Severe night glare

0% Severe starburst


Majority of symptoms were mild, if present

Patient Case


- 58 y/o male S/P myopic LASIK OU with cataracts
- Pre Op:
 - OD: Dsc: 20/30 Nsc: J10
 - OS: Dsc: 20/30 Nsc: J6
 - MRX OD: -0.50 + 1.00 X 170
 - MRX OS: -0.75 + 0.25 X 180



THE LIGHT ADJUSTABLE LENS (LAL)



LAL METHOD OF ACTION



41

As the LAL is postoperatively adjusted to deliver customized vision, there are two major differences in the period after cataract surgery

1 Required wear of ultraviolet (UV) protective glasses




2 Completion of light treatments



- 3 treatments
- 2 lock-ins

The RxSight Light Adjustable Lens (LAL) is the world's first adjustable intraocular lens (IOL) that allows office-based optimization of vision after lens implantation and healing

- The LAL delivers excellent outcomes for cataract patients
- Overcomes limitations of both pre-operative and intra-operative prediction processes
- Drives blended vision process without glare and halos
- Niche- post-refractive



Corrects in 0.25D increments of sphere and cylinder

Corrects down to 0.5 diopters of astigmatism

More Patients with Excellent Results	Comparison IOL	Commercial Data LAL ⁴ (n=121) *Distance Eyes
Percent eyes within 0.50 diopter of sphere	74% ¹	93.4%
Percent eyes within 0.50 diopter of cylinder	62-64% ^{2,3}	90.6%
Percent of eyes 20/20 or better	38-41% ^{2,3}	80.2%

➔ LAL Patients 2x More Likely to See 20/20

1. Lundstrom M. Changing Practice Patterns in Europe? Cataract Refract Surg 2021; 47:373-378

2. Tecos® Toric PMA P98040/S038; FDA Summary of Safety and Effectiveness Data, 2013.

3. AcrySul® Toric P930014/S15; FDA Summary of Safety and Effectiveness Data, 2011

4. RxSight PMA03-002 Clinical Outcomes of Patients Bilaterally Implanted with LAL.

SUMMARY

Refractive Outcomes

- 93.4% within 0.5 D MRSE
- 90.6% within 0.5 D Cylinder
- 2x More LAL Patients See 20/20 UCVA
- 10x Reduced Poor Outcomes (20/40 or worse)

Dysphotopsia profile

- Due to minimized residual refractive error
- No increased glare or halo, no loss of contrast

Intermediate/Reading

- Patients select preferred trade-off between distance, intermediate, and near visual acuity
- Symmetrically broadened defocus curve compared to traditional monofocal IOLs
- 80% 20/20 (distance) and J1 (near) possible

1. RxSight PMA03-002 Clinical Outcomes of Patients Bilaterally Implanted with LAL

2. Tecos® Toric PMA P98040/S038; FDA Summary of Safety and Effectiveness Data, 2013.

3. AcrySul® Toric P930014/S15; FDA Summary of Safety and Effectiveness Data, 2011

4. RxSight PMA03-002 Clinical Outcomes of Patients Bilaterally Implanted with LAL.


Patient Case Outcome




- LAL both eyes implanted
- Post Op: Very happy patient
- OD: Dsc: 20/20 Int: 20/30 Nsc: J5
- OS: Dsc: 20/30 Int: 20/20 Nsc: J2




LAL Outcomes in Post - Refractive Eyes



Number of Eyes

- Total: 154
- S/P RK: 56
- Myopic LASIK/PRK: 66 eyes
- Hyperopic LASIK/PRK: 32 eyes











Patient Case


- 53 year old male with chief complaint of blurry vision in the right eye
- Pre Op:
 - OD: Dsc: 20/80 Nsc: J1
 - OS: Dsc: 20/25 Nsc: J1+
 - MRX OD: -1.75 + 2.75 x 171 20/40
 - MRX OS: -1.50 + 1.25 x 005 20/20

Patient Exam

PACHYMETRY	510	515
PUPILS	No APD	No APD
C/S	White & Quiet	White & Quiet
CORNEA	LASIK Flap, Semi-circular mid stromal scar (paracentral-inferior)	LASIK Flap
ANTERIOR CHAMBER	Normal Depth, Quiet	Normal Depth, Quiet
LENS	1+ NS, Diffuse Cortical Changes	1+ NS
FUNDUS	WNL	WNL




11/Tu/yyyy 11:32:08




Aphera™ IOL Wavefront-Filtering Design

IC⁸
Aphera.
IOL


The Aphera IOL combines the simple, proven principle of small aperture optics with the quality of an aspheric monofocal IOL.




Small Aperture Optics



Large Aperture
Equivalent to a monofocal IOL with a 4.0 mm pupil



Small Aperture
~1.36mm



Aphera
IOL¹

Wavefront-Filtering technology

The IC-8 Aphera IOL is the first small aperture lens that delivers extended depth of focus through its distinctive wavefront-filtering design.

EXTENDED DEPTH OF FOCUS, free from "blurry zones"


EXCELLENT RESULTS REGARDLESS OF ASTIGMATISM
in eyes with as much as 1.5 D of corneal astigmatism

MONOFOCAL-LIKE BINOCULAR CONTRAST SENSITIVITY
in bright and low light conditions



BAUSCH + LOMB

© 2023 Bausch+Lomb APT.00031.USA.23



Patient Post op


- Aphera implanted in OD
- 1 Week Post Op: Very happy patient
- OD: Dsc: 20/25 Nsc: J1

Patient Case

- 66 year old female with chief complaint of increasingly blurry vision
- Pre Op:
 - OD: Dsc: 20/200; Dcc: 20/70
 - OS: Dsc: 20/400; Dcc: 20/80
 - With contact lenses; no improvement in refraction


Exam

PACHYMETRY	511	519
IOP	15	15
PUPILS	No APD	No APD
C/S	White & Quiet	White & Quiet
CORNEA	LASIK Flap, 8 Radials	LASIK Flap, 16 Radials with nasal T cuts
ANTERIOR CHAMBER	Normal Depth, Quiet	Normal Depth, Quiet
LENS	2+ NS, 1+ Cortical	2+ NS, 1+ Cortical
FUNDUS	WNL	WNL



Post-Op

- Aphthera implanted in OU
- Post Op: happy patient
- OD: Dsc: 20/30
- OS: Dsc: 20/200
 - MRX OD: no improvement
 - MRX OS: -4.00 +6.00 x 075 20/80




Clinical Outcomes of the Small Aperture IOL for Complex Corneas with Irregular Astigmatism

Hasan Alsetri, BS, Nicole Fram, MD, Elizabeth Yeu, MD, Eric Donnerfeld, MD, Brandon Ayres, MD, Zaina Al-Mohtaseb, Marisa Schoen, MD, Stephen Kwong, BS, Matthew Santos, MD, Emily Rodgers BS


Small Aperture IOL: Aphthera/IC-8

- Corrects 1.5 astigmatism
- Non dominant -0.75D-1.00 aim
- 1.36mm aperture
- Pinhole test and pilo test
- Ray tracing simulation of small aperture (Itrace)
- May not correct all of the cylinder but will decrease HOA
- Make sure they dilate to 6.5mm-7.0mm for Nd:YAG posterior capsulotomy



Methods

- Non-randomized, multicenter retrospective case series of **51 eyes (46 patients)** who received a small aperture IOL in the setting of corneal disease.
- **IOL Master 700 Barrett True K-RK/Post LVC and Barrett True K Toric (KCN)** with a -0.75 to -1.00 D refractive target were used for planning of IOL power
- **Primary outcomes:** Mean and median absolute errors (AE) and % eyes within 0.50 D, 1.00 D, 1.50D of refractive target were analyzed. Lines of improvement of UCDVA, BCDVA, UCNVA and BCNVA and Refractive Prediction Error.
- **Secondary outcome measures:** symptomatic dimming requiring explanation, need for scleral lens or topography guided PRK




Results


Number of Patients	46
Number of Eyes	51
Age, mean ± SD	66.2 ± 7.8 years
Cyl, mean (range)	-1.65 (-5.5 to 0.76)
RK eyes	16
LASIK eyes	14
KCN eyes	14
Other	7

Clinical Outcomes of the Small Aperture IOL for Complex Corneas with Irregular Astigmatism


Uncorrected Distance: 81% are 20/50 or better




Best Corrected Distance: 75% are 20/30 or better



Uncorrected Near: 77% are 20/40 or better



Best Corrected Near: 85% are 20/30 or better




Visual Acuity/ Lines of Improvement

	Uncorrected Near	Best Corrected Near	Uncorrected Distance	Best Corrected Distance
Baseline	20/62 (0.49)	20/39 (0.29)	20/110 (0.74)	20/46 (0.36)
POM1	20/36 (0.26)	20/25 (0.1)	20/44 (0.34)	20/30 (0.17)
POM3	20/38 (0.28)	20/25 (0.1)	20/38 (0.28)	20/29 (0.16)
Baseline-POM1 (lines improved)	2.6	1.4	6.6	1.6
Baseline-POM3 (lines improved)	2.4	1.4	7.2	1.7
Need for removal due to Dimming	3 patients			


Conclusions

- UCDVA improved by **7.2 lines** and UCNVA improved by **2.4** at 3 months
- **The off-label** use of the small aperture IOL appears to be safe and effective in patients with corneal pathology (and without central scarring).
- Counsel patients regarding the possibility of dimming
- This technology may offer more **hope for contact lens independence** and better spectacle correction in these complex eyes.



65 yold with Restor OU

Vacc	HM	20/40
VA w/ MRX	+10.25 sph 20/20	+0.25 +0.75 x 178 20/20
IOP (central, tonopen)	23	23
Pupils	no apd	No apd
C/S	White and quiet	White and quiet
Cornea	Clear	Clear
Anterior chamber	Vitreous Prolapse	Normal, quiet
Iris	WNL	WNL
Lens	Sunset IOL shifted inferiorly, large anterior capsular opening	Centered PC IOL, PC Intact
Vitreous	WNL	WNL
Fundus exam	WNL	WNL



RIGHT		LEFT	
Date: 12/22/2022	Tech: ZAM, PCKG 1.2.4	Date: 12/22/2022	Tech:
Refraction: 22.81	Vertex: 12.00	Refraction:	Vertex:
AL(Optical):	Adj. AL:	AL(Optical):	Adj. AL:
BCVA:	Hor W-I-W: 11.69	BCVA:	Hor W-I-W:
UCVA:	Phakic ACD:	UCVA:	Phakic ACD:
Sst K1: 45.95 @ 16	Phakic Lens Th:	Sst K1:	Phakic Lens Th:
Sst K2: 46.58 @ 106	Target SEQ Ref: -0.75	Sst K2:	Target SEQ Ref:
Astigm: +0.83 @ 196	Igi Axis:	Astigm:	Igi Axis:
SMVAvg K: 46.23	Alternate K: n: 1.3375	SMVAvg K:	Alternate K:
Additional Data			
Eye Status: Aphakic	PreOp Pathology: No	Eye Status: Phakic	PreOp Pathology: No
New PC Lens: In bag	Prev. IRL: No	New PC Lens: In bag	Prev. IRL: No
	Keratoconus: No		Keratoconus: No
	Scleral Buckle: No		Scleral Buckle: No
	Silicone in Vitreous Cavity: No		Silicone in Vitreous Cavity: No
Formula: Holladay II		Formula:	
Rx Sight/Calhoun Vision	J&J/AMO/Pharmacia/Alrg...	Rx Sight/Calhoun Vision	J&J/AMO/Pharmacia/Alrg...
60605	DIUX	60605	DIUX
MFG ACD(Opt): 5.20	MFG ACD(Opt): 5.72	MFG ACD(Opt): 5.20	MFG ACD(Opt): 5.72
IOL SEQ	SEQ Ref.	IOL SEQ	SEQ Ref.
23.00	-0.11	21.50	-0.35
20.50	-0.45	22.00	-0.69
20.94	-0.75	22.10	-0.75
21.00	-0.79	22.50	-1.01
21.50	-1.13	23.00	-1.35
J&J/AMO/Pharmacia/Alrg...	J&J/AMO/Pharmacia/Alrg...	J&J/AMO/Pharmacia/Alrg...	J&J/AMO/Pharmacia/Alrg...
DIUCO	Tecnis 1-Phaco DCB00	DIUCO	Tecnis 1-Phaco DCB00
MFG ACD(Opt): 5.72	MFG ACD(Opt): 6.63	MFG ACD(Opt): 5.72	MFG ACD(Opt): 6.63
IOL SEQ	SEQ Ref.	IOL SEQ	SEQ Ref.
21.50	-0.30	21.00	-0.17
22.00	-0.69	21.50	-0.49
22.10	-0.75	21.89	-0.75
22.50	-1.01	22.00	-0.82
23.00	-1.35	22.50	-1.15
IOL Consultant Notes			
Surgeon/Technician Notes			

Microsof Pre Ver 2022 0805 WHITSETT VISION GROUP (Reg. 16726055) Page 1 of 1

PROCEDURES
 Exchange of Intraocular lens (66986)

Right eye

PROCEDURE DETAILS
 Procedure Subtype: SURGERY DAY
 Special Needs: N/A Date of surgery: 12/22/2022
 None Surgical Facility: Park Ten Surgical Center
 Surgeon: Zaina Al-Mohstaseb
 Anesthesia: Topical

ASSOCIATED DIAGNOSES

CONCERNS
 Diabetes: No
 Keratoconus: No
 Prior Refractive Surgery: None
 Medication concerns: None
 Allergy concerns: None
 Other concerns: None

COMMENT
 N/A

IOL Model: RxSight LAL +21.00 D
IOL Power: PRE-OP DATA
 Pre-op refraction: +13.25 + 1.12 x 024°
 Anterior keratometry (IOLMaster 700): 0.55 @ 106°
 Posterior keratometry (IOLMaster 700): 0.42 @ 000°
 ZEISS TK (IOLMaster 700): 0.35 @ 125°
 Net astigmatism (D): 0.41 @ 145°
 Average anterior corneal power: 46.22 D
 Axial length: 22.81 mm
 IOL power estimation formula used: Barrett Universal II
 Toric formula used: Barrett Toric

TARGET
 Target range: Distance
 Target refraction: -0.75 D

PREDICTED OUTCOME
 Predicted SE: -0.74 D
 Predicted final refraction: -0.95 + 0.42 x 145°

ARCULATE INCISIONS
 #1: None
 #2: None

LAL Yamane Exchange

LAL Yamane Exchange

[J Cataract Refract Surg](#), 2020 Dec 9.
doi: 10.1097/j.jcrs.0000000000000540. Online ahead of print.

Accuracy of Intraocular Lens Calculation Formulas for Flanged Intrasceral Intraocular Lens Fixation with Double-Needle Technique

Jake McMillin¹, Li Wang, Margaret Y Wang, Zaina Al-Mohtaseb, Sumitra Khandelwal, Mitchell Weikert, M Bowes Hamill

Affiliations [+](#) expand

PMID: 33315743 DOI: 10.1097/j.jcrs.0000000000000540

Abstract

Purpose: To evaluate the refractive prediction error of intraocular lens calculation formulas in eyes that have undergone the Yamane technique for scleral fixation of intraocular lenses (IOL).

Setting: Alkek Eye Center, Cullen Eye Institute, Baylor College of Medicine, Houston, TX DESIGN: Retrospective case series from electronic chart review.

Methods: Patients who had undergone scleral fixation of secondary IOLs were selected. The IOL refractive prediction errors (RPE) for 4 IOL prediction formulas - Barrett Universal II, Holladay 1, Hoffer-Q, and SRK/T - were obtained by subtracting the predicted spherical equivalent from post-operative spherical equivalent. The arithmetic mean RPE, mean absolute error (MAE), and percentages of eyes with prediction error of ≤ 0.5 D and ≤ 1.0 D were calculated and compared.

Results: 40 eyes of the 40 patients met inclusion criteria. All formulas produced hyperopic mean arithmetic RPE. MAE values were 0.73 D for Holladay 1, 0.76 D for Barrett, 0.80 D for SRK/T, and 0.86 D for Hoffer-Q. The percentage of eyes with prediction error of ≤ 0.5 D and ≤ 1.0 D with these formulas were: 45% (18 eyes) and 75% (30 eyes) for Holladay 1, 38.5% (15 eyes) and 77% (30 eyes) for Barrett, 32.5% (13 eyes) and 67.5% (27 eyes) for SRK/T, and 27.5% (11 eyes) and 62.5% (25 eyes) with Hoffer-Q. There were no significant differences in prediction errors between the 4 formulas.

Conclusion: Refractive outcomes of the Yamane technique are less predictable than standard cataract surgery. Arithmetic RPE is hyperopic to predicted for all formulas tested.

Thank You
What Questions Do you Have?
zaina1225@gmail.com